Rhumbline Advisers Boosts Holdings in Alignment Healthcare, Inc. $ALHC

Rhumbline Advisers increased its stake in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 4.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 141,638 shares of the company’s stock after buying an additional 5,934 shares during the period. Rhumbline Advisers owned about 0.07% of Alignment Healthcare worth $2,637,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. MCF Advisors LLC boosted its holdings in Alignment Healthcare by 87.6% in the first quarter. MCF Advisors LLC now owns 2,165 shares of the company’s stock worth $40,000 after purchasing an additional 1,011 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new stake in Alignment Healthcare in the first quarter worth about $42,000. Amalgamated Bank lifted its holdings in Alignment Healthcare by 21.6% in the first quarter. Amalgamated Bank now owns 3,466 shares of the company’s stock worth $65,000 after purchasing an additional 616 shares during the period. Regal Partners Ltd bought a new stake in Alignment Healthcare in the first quarter worth about $194,000. Finally, CWM LLC raised its position in Alignment Healthcare by 137.6% in the first quarter. CWM LLC now owns 10,553 shares of the company’s stock worth $196,000 after acquiring an additional 6,112 shares in the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Alignment Healthcare Trading Up 1.3%

NASDAQ:ALHC opened at $16.54 on Wednesday. The stock has a market capitalization of $3.28 billion, a PE ratio of -59.07 and a beta of 1.17. The business’s 50-day simple moving average is $14.52 and its 200-day simple moving average is $15.55. The company has a debt-to-equity ratio of 2.29, a current ratio of 1.66 and a quick ratio of 1.66. Alignment Healthcare, Inc. has a fifty-two week low of $9.15 and a fifty-two week high of $21.06.

Alignment Healthcare (NASDAQ:ALHC) last released its earnings results on Wednesday, July 30th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.14. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $960.25 million. Alignment Healthcare had a negative return on equity of 43.68% and a negative net margin of 1.53%.The business’s quarterly revenue was up 49.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.13) EPS. Alignment Healthcare has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts expect that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Insider Activity at Alignment Healthcare

In other news, Director Joseph S. Konowiecki sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $17.00, for a total transaction of $425,000.00. Following the sale, the director owned 1,127,049 shares in the company, valued at $19,159,833. This represents a 2.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO John E. Kao sold 355,018 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $16.41, for a total value of $5,825,845.38. Following the sale, the chief executive officer owned 4,533,568 shares in the company, valued at approximately $74,395,850.88. This represents a 7.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,142,077 shares of company stock worth $18,068,259. Insiders own 6.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on ALHC. KeyCorp raised Alignment Healthcare from a “sector weight” rating to an “overweight” rating and set a $21.00 target price on the stock in a research note on Monday, August 25th. Stephens raised Alignment Healthcare to a “strong-buy” rating in a research report on Monday, June 2nd. Zacks Research upgraded Alignment Healthcare to a “hold” rating in a report on Friday, August 8th. Wall Street Zen lowered Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Barclays raised Alignment Healthcare from an “underweight” rating to an “equal weight” rating and raised their target price for the stock from $9.00 to $13.00 in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Alignment Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $18.83.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.